GMAB News and Press, Genmab A/S From 12/21/23

2023-12-21 13:05:16 ET Summary Valuations in the biotech market have fallen, making it a good time for acquisitions in the industry. Investors should focus on commercial-stage biotech companies that generate revenue, as they provide a safety net in uncertain economic conditions. ...

2023-12-14 12:25:24 ET Summary Biopharmaceutical sector valuations have become more attractive after a significant decline in 2021. Larger drug companies are making acquisitions and partnerships with small-cap stocks at generous premiums. Money managers are under-invested in t...

2023-12-12 13:17:41 ET More on Johnson & Johnson Johnson & Johnson Vs. Pfizer: Better Pharma Stock? Stocks To Watch: Big Week On Tap For McDonald's, Shopify, GameStop, And Johnson & Johnson Johnson & Johnson: Sleep Well At Night With The Only AAA-Rate...

2023-12-11 10:30:00 ET Stock Traders Daily has produced this trading report using a proprietary method.  This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...

2023-12-11 06:20:03 ET AbbVie ( NYSE: ABBV ) and Genmab ( GMAB ) on Saturday presented latest trial data for their lymphoma drug candidate epcoritamab in patients with difficult-to-treat relapsed/refractory (R/R) follicular lymphoma (FL). Updated data from Phase 1/2 EPCO...

New Data for Bispecific Antibody Epcoritamab (DuoBody® CD3xCD20) Shows Strong, Durable Treatment Response for Patients with Difficult-To-Treat Relapsed/Refractory (R/R) Follicular Lymphoma (FL) PR Newswire - Data from Phase 1/2 EPCORE™ NHL-1 study show patients tre...

Data from the pivotal phase 1/2 EPCORE™ NHL-1 study showed 82 percent overall response rate (ORR), 63 percent complete response (CR) and 67 percent minimal residual disease (MRD) negativity in patients with relapsed/refractory (R/R) follicular lymphoma (FL) treated with subcutaneous epcori...

2023-12-05 17:01:54 ET Gainers: Atea Pharmaceuticals ( AVIR ) +5% . The Lovesac Company ( LOVE ) +5% . MSP Recovery ( LIFW ) +4% . Huntington Bancshares  ( HBANL ) +3% . Genmab  ( GMAB ) +3% . Losers: Fluence En...

2023-12-03 12:00:30 ET More on SPDR S&P Biotech ETF Ideal Pairs Trade Into 2024: Health Vs. Hype: Capitalizing On A Therapeutic Turn And A Tech Tumble Biopharma Bounce-Back: From Policy Pains To Profitable Plains Biotechs rally with gene editing stocks among nota...

2023-11-27 08:03:06 ET More on AbbVie, Genmab, etc. AbbVie Vs. Amgen: How Peter Lynch Picks Dividend Stocks Genmab A/S (GMAB) Q3 2023 Earnings Call Transcript Genmab A/S 2023 Q3 - Results - Earnings Call Presentation AbbVie suing Sandoz, four others to block ...